A Lucky Baby: Maternal Valsartan Use During Pregnancy

Several published cases suggest that the use of angiotensin II receptor antagonists is fetotoxic during the third trimester, but not in early pregnancy. 41 years-old a woman with well-controlled chronic hypertension has been treated with valsartan 160 mg/day until pregnancy was diagnosed at 25 weeks of gestation. Then, valsartan was discontinued; alfa-metildopa 500 mg/ day was started. Dose of metildopa was intensified to 1000 mg/ day until taking under control of blood pressure. In our patient, amniotic fluid volume abnormalities and fetal anomalies were not observed until end of pregnancy on successive obstetric ultrasonography. After delivery, we did not observe neonatal renal disorder and other medical problems. Growth parameters of baby were within the normal range, and there was no evidence of developmental delay.In our case, we presented a case of fortunate pregnant using valsartan, angiotensin II receptor antagonist (ARB), during her first and second trimester of her pregnancy.